Should a patient’s access to transplant and HCC care depend on where they live in Canada? Practices across Canadian transplant programs still differ on key decisions, from listing to long-term follow-up, and these differences can lead to unequal outcomes. This consensus session will bring together experts from across the country to look at where practice differs and where it should be harmonized. It will address key issues pre-transplant such as MELD exception points and caps, and total tumour volume (TTV) and AFP criteria. And it will also look at issues post-transplant, such as immunotherapy use, imaging surveillance, and recurrent HCC management. Using expert panels and audience polling, participants will help shape national recommendations aimed at reducing disparities and making transplant care for HCC consistent across Canada.
and Learning Objectives